24Jul/13

Harbour Antibodies BV Raises ‚Ǩ2.5M ($3.3M) to Accelerate the Development … – PharmiWeb.com (press release)

Harbour Antibodies BV Raises ‚Ǩ2.5M ($3.3M) to Accelerate the Development …
PharmiWeb.com (press release)
Harbour Antibodies BV the creator of transgenic mice to aid in the discovery of new human antibody-based therapies has raised ‚Ǩ2.5M ($3.3M) to continue R&D and commercialize its technologies. The round was led by Atlas Venture. With the funding …
Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription)

all 4 news articles »

24Jul/13

Texas Children's Hospital ranks #3 nationally in cardiology and heart surgery … – The Herald | HeraldOnline.com

Texas Children’s Hospital ranks #3 nationally in cardiology and heart surgery …
The Herald | HeraldOnline.com
… Center include cardiac catheterization, electrophysiology, diagnostic and cardiac imaging, adult congenital heart disease treatment, congenital heart surgery, cardiac nursing, cardiac critical care (cardiovascular intensive care unit) and heart …

and more »

24Jul/13

Pneumonie à Pneumocystis : une complication des traitements par rituximab – Journal International de Médecine (Inscription)

Pneumonie à Pneumocystis : une complication des traitements par rituximab
Journal International de Médecine (Inscription)
La pneumonie à Pneumocystis (PP) reste une infection fongique grave affectant les malades immunodéprimés. Les défenses immunitaires principales contre ce germe opportuniste sont constitués classiquement par les lymphocytes T CD4 +. Mais des études …